Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Takeda Pharmaceutical Company Limited TAK
$16.38
+$0.22 (1.33%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
50389837633.00000000
-
week52high
17.15
-
week52low
12.28
-
Revenue
3569006000000
-
P/E TTM
26
-
Beta
0.68091600
-
EPS
0.64000000
-
Last Dividend
0.66000000
-
Next Earnings Date
10 мая 2023 г. в 04:00
Описание компании
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cowen & Co. | Outperform | Market Perform | 19 июл 2022 г. |
| Morgan Stanley | Equal-Weight | Overweight | 07 окт 2021 г. |
| JP Morgan | Overweight | Overweight | 11 мар 2020 г. |
| Cowen & Co. | Market Perform | 01 ноя 2019 г. | |
| Jefferies | Buy | 24 сент 2019 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Takeda Pharmaceutical Company Limited (TAK) Q4 2022 Earnings Call Transcript
Seeking Alpha
11 мая 2023 г. в 22:42
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q4 2022 Results Conference Call May 11, 2023 6:00 AM ET Company Participants Christopher O'Reilly - Global Head of IR & Global Finance Christophe Weber - President, CEO & Representative Director Andrew Plump - President of Research & Development and Representative Director Constantine Saroukos - CFO & Representative Director Julie Kim - President of the U.S. Business Unit & U.S. Country Head Giles Platford - President of the Plasma-Derived Therapies Business Unit Ramona Sequeira - President of Global Portfolio Division Conference Call Participants Yamaguchi-san - Citigroup Tony Ren - Macquarie Mamegano-san - BofA Securities Muraoka-san - Morgan Stanley Michael Nedelcovych - TD Cowen Miki Sogi - Bernstein Christopher O'Reilly Thank you very much for joining FY 2022 earnings announcement of Takeda. I will serve as MC, Head of IR.
Why Do We Keep Buying Takeda Pharmaceutical Shares
Seeking Alpha
03 апр 2023 г. в 03:51
Sales of Takhzyro amounted to 44.1 billion Japanese yen in the 3rd quarter of 2022, an increase of 42.7% from the previous year. Takeda Pharmaceutical's revenue was $8,354 million in Q3 2022, showing phenomenal growth both year-on-year and quarter-on-quarter.
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Zacks Investment Research
30 мар 2023 г. в 11:23
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Price Growth & Yield: For That Magical Combo, Leave the U.S.
MarketBeat
21 мар 2023 г. в 12:01
It's not often you find one stock with sustained price growth and solid dividend yield, but three foreign stocks, Takeda Pharmaceutical Co., Ltd. (NYSE: TAK), United Microelectronics Corp. (NYSE: UMC) and Coca-Cola FEMSA SAB de CV (NYSE: KOF) are showing that magical combination.
Big Stocks Making New Highs Despite Everything
Forbes
18 мар 2023 г. в 14:50
Interest rates may be headed higher and regional banks may be in trouble but that hasn't stopped just a few stocks from hitting new highs.